1stOncology™: Cancer Intelligence Service – Page 8216 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Signify Health and HealthComp collaborate to develop value-based health benefits

On September 30, 2021 Signify Health (NYSE: SGFY), a leading value-based healthcare platform that leverages advanced analytics, technology and nationwide healthcare provider networks, and HealthComp, the largest independent health benefits administrator in the country, reported a new strategic collaboration to give self-funded employer groups an affordable health benefits package that embeds value-based payments with value-based benefits design (Press release, Signify Health, SEP 30, 2021, https://www.signifyhealth.com/news/signify-health-and-healthcomp-collaborate-to-develop-value-based-health-benefits [SID1234590621]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"Having successfully built a value-based care platform to support providers, employers, and health plans who are committed to improving patient outcomes, our collaboration with a leading third-party administrator such as HealthComp opens up new opportunities to drive the transformation away from the broken fee for service model," said Peter Boumenot, Chief Product Officer, Signify Health. "We believe that converging value-based payments with value-based benefit design is essential for all stakeholders at both the individual and the population levels. HealthComp’s proven capabilities will help us bridge this gap for employers across the country who are looking for turnkey solutions that improve costs and outcomes."

"The majority of the employers we work with are looking for new ways to strengthen the alignment of cost, quality and member satisfaction with their benefits offerings," said Justin Tran, Senior Vice President of medical cost management at HealthComp. "By working with Signify Health, we have a unique opportunity to bring together advanced alternative payment models with advanced benefits designs that deliver the clinical and operational excellence needed to address the root causes of suboptimal health outcomes and increasing costs."

Employers are increasingly adopting value-based insurance designs (VBID), which align the appropriate use of high value healthcare services with the engagement of high-performance providers who are accountable for health outcomes. A new white paper published by VBID Health describes how VBID and alternative payment models can be brought together to improve overall health and lower the costs of healthcare delivery and references many of the tools that are available for employers working in collaboration with providers, third-party administrators, and carriers. Early results of similar payment arrangements with Signify Health have shown a promising reduction in both health plan spend and adverse clinical events for members engaged in the program.

The partnership will focus on leveraging Signify Health’s leading capabilities in episode-based financing and high-value provider networks, along with HealthComp’s innovative approach to comprehensive benefits administration and member engagement, to create more affordable, predictable, transparent, and member-focused benefit design. Value-based benefits developed by HealthComp and powered by Signify Health’s value-based payment platform will be offered in select markets across the U.S.

LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma

On September 30, 2021 VECT-HORUS reported to be part of the research in PDAC with its theranostic agents to first improve PDAC diagnosis, response monitoring or recurrence detection in operated patients and also treat them (Press release, Vect-Horus, SEP 30, 2021, View Source [SID1234590620]).
Cedric malicet, Oncology Department Manager, is pleased to inform you of the recent publication of the article " LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma " in Communications Biology.

Regulus Therapeutics’ Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science

On September 30, 2021 Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), reported that David Baltimore, Ph.D., a director of Regulus, is the recipient of the 2021 Lasker-Koshland Special Achievement Award in the category of Medical Science (Press release, Regulus, SEP 30, 2021, View Source [SID1234590618]).

Dr. Baltimore’s recognition is based on the breadth and substance of his discoveries in virology, immunology, and cancer as well as his leadership within the academic and scientific communities and his extensive work as a public advocate for science.

The Lasker Awards program honors discoveries and clinical advances that improve human health and highlights the importance of public support for science. The awards program is widely considered one of the most prestigious awards programs in medical science and numerous recipients, including Dr. Baltimore, also hold Nobel Prizes.

"On behalf of the Regulus team, we congratulate David for this recognition of his extensive and impressive body of work," said Jay Hagan, President and Chief Executive Officer of Regulus. "As a 1975 Nobel Prize winner in Physiology or Medicine, David has made multiple foundational scientific discoveries over the course of his career, including the discovery of reverse transcriptase, as well as his additional research, which has contributed broadly to our understanding of cancer, AIDS, and the underlying biology of the immune response. He has been a powerful advocate for science over the years, advancing work that helped America respond to the AIDS crisis, and has played a significant role in the development of the biotechnology industry in America. We are proud that he is a part of Regulus and continually benefit from his guidance as we advance our pipeline of microRNA therapeutics."

More information about the foundation and the Special Achievement Award can be found here.

About David Baltimore, Ph.D.

Dr. David Baltimore is a Director of Regulus and President Emeritus and Distinguished Professor of Biology at Caltech. Awarded the Nobel Prize in 1975, Dr. Baltimore has profoundly influenced national science policy on such issues as recombinant DNA research and the AIDS epidemic. Dr. Baltimore graduated from Swarthmore College with a degree in chemistry. He took graduate courses at Massachusetts Institute of Technology and received his Ph.D. from Rockefeller University. He was a postdoctoral fellow at MIT and Albert Einstein College of Medicine. He was a Research Associate at The Salk Institute in 1965 and joined the faculty at MIT in 1968. He has served as Director of the Whitehead Institute for Biomedical Research, President of Rockefeller University, and President of Caltech. He was awarded the 1999 National Medal of Science and 2000 Warren Alpert Foundation Prize. He is a member of the National Academy of Sciences, fellow of the American Academy of Arts and Sciences, and a foreign member of the Royal Society of London and the French Academy of Sciences. He has also been President and Chair of the American Association of the Advancement of Science.

ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

On September 30, 2021 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported three poster presentations at the AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) to be held October 7-10, 2021 (Press release, ORIC Pharmaceuticals, SEP 30, 2021, View Source [SID1234590617]).

Details of the poster presentations are as follows:

Title: Initial results from a Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer
Poster #: P041

Title: Biomarker results supporting selection of RP2D from a Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide
Poster #: P015

Title: ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetrant properties and enhanced potency in preclinical studies of HER2-positive breast cancer
Poster #: P234
Full abstracts and poster presentations will be available for on-demand viewing via the online platform for AACR (Free AACR Whitepaper)-NCI-EORTC on October 7, 2021, at 9 a.m. ET.

Company Webcast and Conference Call

ORIC will host a webcast and conference call to review data presented at AACR (Free AACR Whitepaper)-NCI-EORTC on Thursday, October 7, 2021, at 9:00 a.m. ET. To participate in the conference call, please dial (833) 651-0991 (domestic) or (918) 922-6080 (international) and refer to conference ID 3575856. A live webcast and audio archive of the conference call will be available through the investor section of the company’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck

On September 30, 2021 Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, reported that Merck, known as MSD outside the United States and Canada, has extended the research term for the first cytokine derivative program under the 2018 Merck Agreement, for an additional two years (Press release, Sutro Biopharma, SEP 30, 2021, View Source [SID1234590607]). The research extension is intended to facilitate completion of preclinical research and development activities for a second candidate, which has a novel design and approach. As part of this extension, Sutro is eligible to receive up to $10 million.

"We are encouraged by the strength of the continued research efforts in collaboration with Merck on the cytokine derivative programs," said Trevor Hallam, President of Research and Chief Scientific Officer of Sutro. "This research extension has the potential to produce an additional candidate using a different approach towards the same target. We believe that this productive research program underscores the potential of Sutro’s platform to engineer therapeutics with novel design and approach."

About the Merck Collaboration
Under the terms of the 2018 Merck collaboration agreement, Sutro and Merck are conducting preclinical research and development of cytokine derivatives utilizing Sutro’s proprietary cell-free protein synthesis and site-specific conjugation platforms, XpressCF and Xpress CF+. Merck has exclusive worldwide rights to therapeutic candidates derived from the collaboration. In March 2020, Merck exercised its option to extend the research term of the first collaboration program by one year, which generated a payment of $5 million to Sutro. In April 2021, Merck initiated IND-enabling toxicology studies for the first candidate under the first collaboration program for which Sutro earned a $15 million milestone payment. Additionally, research on a second cytokine derivative program on a separate target is ongoing.